Steven H Marshall
Overview
Explore the profile of Steven H Marshall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
834
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jacobs M, Good C, Abdelhamed A, Mack A, Bethel C, Marshall S, et al.
Antimicrob Agents Chemother
. 2024 Oct;
68(12):e0112724.
PMID: 39475259
Ledaborbactam (formerly VNRX-5236), a bicyclic boronate β-lactamase inhibitor with activity against class A, C, and D β-lactamases, is under development as an orally bioavailable etzadroxil prodrug (VNRX-7145) in combination with...
2.
Yasmin M, Marshall S, Chen L, Rhoads D, Jacobs M, Rojas L, et al.
Antimicrob Agents Chemother
. 2024 Aug;
68(10):e0020824.
PMID: 39162528
We characterized the molecular determinants of meropenem-vaborbactam (MV) non-susceptibility among non-metallo-β-lactamase-producing KPC- (KPC-). Whole-genome sequencing was performed to identify mutations associated with MV non-susceptibility. Isolates with elevated MV MICs were...
3.
De la Cadena E, Mojica M, Rojas L, Castro B, Garcia-Betancur J, Marshall S, et al.
Microbiol Spectr
. 2024 May;
12(6):e0410523.
PMID: 38700337
Importance: Latin America and the Caribbean is an endemic region for carbapenemases. Increasingly high rates of carbapenemase (KPC) have established ceftazidime-avibactam (CZA) as an essential antimicrobial for the treatment of...
4.
Mezcord V, Traglia G, Pasteran F, Escalante J, Lopez C, Wong O, et al.
Int J Antimicrob Agents
. 2024 Mar;
63(5):107131.
PMID: 38432605
No abstract available.
5.
Logan L, Coy L, Pitstick C, Marshall S, Medernach R, Domitrovic T, et al.
Front Cell Infect Microbiol
. 2023 Oct;
13:1249505.
PMID: 37900312
Introduction: Fluoroquinolones (FQs) are not commonly prescribed in children, yet the increasing incidence of multidrug-resistant (MDR) Enterobacterales (Ent) infections in this population often reveals FQ resistance. We sought to define...
6.
Hujer A, Marshall S, Mack A, Hujer K, Bakthavatchalam Y, Umarkar K, et al.
mBio
. 2023 Oct;
14(6):e0111823.
PMID: 37889005
Compared to other genera of Gram-negative pathogens, is adept in acquiring complex non-enzymatic and enzymatic resistance mechanisms thus remaining a challenge to even novel antibiotics including recently developed β-lactam and...
7.
Holger D, El Ghali A, Bhutani N, Lev K, Stamper K, Kebriaei R, et al.
Antimicrob Agents Chemother
. 2023 Oct;
67(11):e0057823.
PMID: 37855639
Biofilm-producing infections pose a severe threat to public health and are responsible for high morbidity and mortality. Phage-antibiotic combinations (PACs) are a promising strategy for combatting multidrug-resistant (MDR), extensively drug-resistant...
8.
Morelli M, Kloosterboer A, Fulton S, Furin J, Newman N, Omar A, et al.
Antimicrob Agents Chemother
. 2023 May;
67(7):e0027723.
PMID: 37166191
Resistant Gram-negative bacteria are a growing concern in the United States, leading to significant morbidity and mortality. We identified a 72-year-old female patient who presented with unilateral vision loss. She...
9.
Yasmin M, Rojas L, Marshall S, Hujer A, Cmolik A, Marshall E, et al.
Open Forum Infect Dis
. 2023 Feb;
10(2):ofad014.
PMID: 36820316
Background: is an emerging Gram-negative nonlactose fermenter in the health care setting, where it causes life-threatening infections in immunocompromised patients. We aimed to characterize the molecular mechanisms of antimicrobial resistance...
10.
Ruegsegger L, Xiao J, Naziripour A, Kanumuambidi T, Brown D, Williams F, et al.
Antimicrob Agents Chemother
. 2022 Sep;
66(9):e0068822.
PMID: 36066237
Patients with burn injuries are at high risk for infectious complications, and infections are the most common cause of death after the first 72 h of hospitalization. Hospital-acquired infections caused...